Trial Profile
Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Servier
- 26 May 2020 Status changed from active, no longer recruiting to completed.
- 25 Jan 2020 Efficacy and safety results from the expansion part of the trial presented at the 2020 Gastrointestinal Cancers Symposium.
- 03 Oct 2019 Planned End Date changed from 24 Jan 2020 to 30 Jun 2020.